Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Journal of Coloproctology (Rio de Janeiro. Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632011000300002 |
Resumo: | Introduction: Adalimumab (ADA) is a subcutaneous fully-human anti-TNF antibody which has a significant role in the management of Crohn's disease (CD). Its efficacy has been demonstrated in several clinical trials. The main objective of this study was to evaluate the role of ADA in the induction of clinical remission in a Brazilian series of CD cases. Method: A retrospective analysis of CD patients treated with ADA was performed in three Brazilian inflammatory bowel diseases (IBD) reference centers. The following characteristics were analyzed: gender, age, indication to ADA treatment, type of response, previous exposure to infliximab (IFX), concomitant use of immunomodulators and adverse events, among others. Results: 54 patients (29 females) were included in this series, with mean age of 36.72 years (ranging from 15 to 62 years). After induction regimen, 26 patients (48.14%) were in clinical remission, 26 (48.14%) had partial response, and 2 (3.72%) were primary non-responders. After a mean follow-up of 9.83 (2 to 28) months, 17 patients (31.48%) presented adverse events. The most common event was pain on the injection site (7 patients - 12.96%). Conclusions: ADA was effective to induce CD remission in this Brazilian case series. The remission and response rates were similar to the literature, as well as the safety profile of this drug. |
id |
SBCP-1_c84e3dc10fdd85ab3e2726f100ecbb92 |
---|---|
oai_identifier_str |
oai:scielo:S2237-93632011000300002 |
network_acronym_str |
SBCP-1 |
network_name_str |
Journal of Coloproctology (Rio de Janeiro. Online) |
repository_id_str |
|
spelling |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case seriesCrohn's diseasetumor necrosis factor-alpharemission inductionantibodies, monoclonalIntroduction: Adalimumab (ADA) is a subcutaneous fully-human anti-TNF antibody which has a significant role in the management of Crohn's disease (CD). Its efficacy has been demonstrated in several clinical trials. The main objective of this study was to evaluate the role of ADA in the induction of clinical remission in a Brazilian series of CD cases. Method: A retrospective analysis of CD patients treated with ADA was performed in three Brazilian inflammatory bowel diseases (IBD) reference centers. The following characteristics were analyzed: gender, age, indication to ADA treatment, type of response, previous exposure to infliximab (IFX), concomitant use of immunomodulators and adverse events, among others. Results: 54 patients (29 females) were included in this series, with mean age of 36.72 years (ranging from 15 to 62 years). After induction regimen, 26 patients (48.14%) were in clinical remission, 26 (48.14%) had partial response, and 2 (3.72%) were primary non-responders. After a mean follow-up of 9.83 (2 to 28) months, 17 patients (31.48%) presented adverse events. The most common event was pain on the injection site (7 patients - 12.96%). Conclusions: ADA was effective to induce CD remission in this Brazilian case series. The remission and response rates were similar to the literature, as well as the safety profile of this drug.Sociedade Brasileira de Coloproctologia2011-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632011000300002Journal of Coloproctology (Rio de Janeiro) v.31 n.3 2011reponame:Journal of Coloproctology (Rio de Janeiro. Online)instname:Sociedade Brasileira de Coloproctologia (SBCP)instacron:SBCP10.1590/S2237-93632011000300002info:eu-repo/semantics/openAccessKotze,Paulo GustavoVieira,AndreaSobrado Junior,Carlos WalterSalem,Juliana BarretoKotze,Lorete Maria da Silvaeng2012-05-07T00:00:00Zoai:scielo:S2237-93632011000300002Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=2237-9363&lng=pt&nrm=isohttps://old.scielo.br/oai/scielo-oai.php||sbcp@sbcp.org.br2317-64232237-9363opendoar:2012-05-07T00:00Journal of Coloproctology (Rio de Janeiro. Online) - Sociedade Brasileira de Coloproctologia (SBCP)false |
dc.title.none.fl_str_mv |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
title |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
spellingShingle |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series Kotze,Paulo Gustavo Crohn's disease tumor necrosis factor-alpha remission induction antibodies, monoclonal |
title_short |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
title_full |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
title_fullStr |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
title_full_unstemmed |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
title_sort |
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series |
author |
Kotze,Paulo Gustavo |
author_facet |
Kotze,Paulo Gustavo Vieira,Andrea Sobrado Junior,Carlos Walter Salem,Juliana Barreto Kotze,Lorete Maria da Silva |
author_role |
author |
author2 |
Vieira,Andrea Sobrado Junior,Carlos Walter Salem,Juliana Barreto Kotze,Lorete Maria da Silva |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Kotze,Paulo Gustavo Vieira,Andrea Sobrado Junior,Carlos Walter Salem,Juliana Barreto Kotze,Lorete Maria da Silva |
dc.subject.por.fl_str_mv |
Crohn's disease tumor necrosis factor-alpha remission induction antibodies, monoclonal |
topic |
Crohn's disease tumor necrosis factor-alpha remission induction antibodies, monoclonal |
description |
Introduction: Adalimumab (ADA) is a subcutaneous fully-human anti-TNF antibody which has a significant role in the management of Crohn's disease (CD). Its efficacy has been demonstrated in several clinical trials. The main objective of this study was to evaluate the role of ADA in the induction of clinical remission in a Brazilian series of CD cases. Method: A retrospective analysis of CD patients treated with ADA was performed in three Brazilian inflammatory bowel diseases (IBD) reference centers. The following characteristics were analyzed: gender, age, indication to ADA treatment, type of response, previous exposure to infliximab (IFX), concomitant use of immunomodulators and adverse events, among others. Results: 54 patients (29 females) were included in this series, with mean age of 36.72 years (ranging from 15 to 62 years). After induction regimen, 26 patients (48.14%) were in clinical remission, 26 (48.14%) had partial response, and 2 (3.72%) were primary non-responders. After a mean follow-up of 9.83 (2 to 28) months, 17 patients (31.48%) presented adverse events. The most common event was pain on the injection site (7 patients - 12.96%). Conclusions: ADA was effective to induce CD remission in this Brazilian case series. The remission and response rates were similar to the literature, as well as the safety profile of this drug. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632011000300002 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632011000300002 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S2237-93632011000300002 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Coloproctologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Coloproctologia |
dc.source.none.fl_str_mv |
Journal of Coloproctology (Rio de Janeiro) v.31 n.3 2011 reponame:Journal of Coloproctology (Rio de Janeiro. Online) instname:Sociedade Brasileira de Coloproctologia (SBCP) instacron:SBCP |
instname_str |
Sociedade Brasileira de Coloproctologia (SBCP) |
instacron_str |
SBCP |
institution |
SBCP |
reponame_str |
Journal of Coloproctology (Rio de Janeiro. Online) |
collection |
Journal of Coloproctology (Rio de Janeiro. Online) |
repository.name.fl_str_mv |
Journal of Coloproctology (Rio de Janeiro. Online) - Sociedade Brasileira de Coloproctologia (SBCP) |
repository.mail.fl_str_mv |
||sbcp@sbcp.org.br |
_version_ |
1752126476934709248 |